The invention belongs to the technical field of medicine, and particularly relates to a novel anti-PD-1 antibody. The novel anti-PD-1 antibody is prepared from heavy chain CDR sequences selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:33, SEQ ID NO:35 and SEQ ID NO:37 as the novel anti-PD-1 antibody can interdict combination of PD-1 ligand and a programmed death molecule 1 (PD-1), the inhibiting effect of the PD-1 ligand on a T cell for expressing PD-1 is interdicted. The novel anti-PD-1 antibody provides a quite-effective reagent for treating multiple cancers by adjusting the human immunologic function.
